Gland Pharma Elevates Srinivas Sadu to Executive Chairman and CEO

Hyderabad-based Gland Pharma has announced a significant leadership change with the appointment of Srinivas Sadu as the Executive Chairman and Chief Executive Officer (CEO), effective from June 10, 2024. This announcement came through a regulatory filing on Friday, marking a pivotal shift in the company's management structure.

Srinivas Sadu, who has been serving as the Managing Director and CEO since April 25, 2019, will take over the new roles, bringing his extensive experience spanning over two decades within the pharmaceutical industry. Sadu's journey with Gland Pharma started in 2000, and he has played a critical role in the company's ascendancy through various leadership roles, including that of Chief Operating Officer in 2011.

This leadership elevation is seen as a strategic move to further harness Sadu’s deep understanding of the pharmaceutical sector and drive Gland Pharma’s growth and expansion strategies. Under his leadership, the company is expected to continue its trajectory of innovation and market expansion, particularly focusing on enhancing its presence in global markets.

The company, renowned for its significant contributions to the pharmaceutical industry, especially during the COVID-19 pandemic with the production of over 100 million doses of vaccines, is poised for its next phase of growth. This transition in leadership is also aimed at reinforcing Gland Pharma's commitment to delivering high-quality medicines and expanding its reach in underserved rare disease communities.